Analyst consensus rating
Dermata Therapeutics Analyst Rating: Buy
DRMA is rated Buy by 1 analysts with a $4.00 target. As of 2026-08-24.
Direct answer
Dermata Therapeutics's consensus rating is Buy.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $4.00.
Forecast evidence checked August 24, 2026.
Get free Dermata Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.63
- Average price target
- $4.00
- High price target
- $4.00
- Low price target
- $4.00
- Low target gap
- +145.4%
- Target upside
- +145.4%
- High target gap
- +145.4%
- Target range width
- 0%
- Consensus rating
- Buy
- Analysts
- 1
- Evidence date
- August 24, 2026
- Valid through
- August 31, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Dermata Therapeutics?
Dermata Therapeutics has a verified Buy consensus. The same dataset has an average price target of $4.00.
How far are Dermata Therapeutics's low and high targets from the recorded price?
The low target implies +145.4%, while the high target implies +145.4%.
How many analysts are included in Dermata Therapeutics's consensus?
The verified consensus includes 1 analysts.
How is Dermata Therapeutics's target upside or downside calculated?
The average target of $4.00 is divided by the recorded price of $1.63, then one is subtracted to produce +145.4%. This does not guarantee a future return.
When was Dermata Therapeutics's analyst forecast verified?
The data was verified on 2026-08-24. The dataset is valid through 2026-08-31.